Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer cell"
DOI: 10.1016/j.ccell.2017.02.002
Abstract: We identified B cell maturation antigen (BCMA) as a potential therapeutic target in 778 newly diagnosed and relapsed myeloma patients. We constructed an IgG-based BCMA-T cell bispecific antibody (EM801) and showed that it increased CD3+… read more here.
Keywords: myeloma; cell bispecific; bcma cell; antibody em801 ... See more keywords
Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement
Sign Up to like & getrecommendations! Published in 2022 at "Immunological Investigations"
DOI: 10.1080/08820139.2022.2131569
Abstract: ABSTRACT T-cell bispecific antibodies (T-BsAbs) are a new class of cancer immunotherapy drugs that can simultaneously bind to tumor-associated antigens on target cells and to the CD3 subunit of the T-cell receptor (TCR) on T… read more here.
Keywords: cell; factors affecting; cell bispecific; efficacy ... See more keywords
p95HER2–T cell bispecific antibody for breast cancer treatment
Sign Up to like & getrecommendations! Published in 2018 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.aat1445
Abstract: T cell bispecific antibodies against an isoform of HER2 effectively target many HER2-expressing tumors but not normal tissues. Fine-tuning HER2 targeting HER2 receptor tyrosine kinase is frequently overexpressed in breast and gastric cancer. HER2-overexpressing tumors… read more here.
Keywords: targeting her2; p95her2; breast; cell bispecific ... See more keywords
Abstract 3634: A novel tumor-targeted 4-1BB agonist and its combination with T-cell bispecific antibodies: an off-the-shelf cancer immunotherapy alternative to CAR T-cells
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3634
Abstract: Immune cell costimulation via 4-1BB agonism has shown anti-tumor activity in the clinic and is an important element of next-generation chimeric-antigen-receptor (CAR) adoptive T-cell therapy approaches. However, the clinical development of first-generation, 4-1BB agonistic antibodies… read more here.
Keywords: combination; cell bispecific; generation; cancer ... See more keywords
Abstract LB-292: p95HER2-T cell bispecific antibody for breast cancer treatment
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-lb-292
Abstract: T cell bispecific antibodies (TCBs) are engineered molecules that include, within a single entity, binding sites to the T cell receptor and to a tumor-specific or a tumor-associated antigen. The receptor tyrosine kinase HER2 is… read more here.
Keywords: p95her2; breast; cell bispecific; cancer ... See more keywords
T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
Sign Up to like & getrecommendations! Published in 2021 at "Pharmaceuticals"
DOI: 10.3390/ph14111172
Abstract: As a breakthrough immunotherapy, T cell bispecific antibodies (T-BsAbs) are a promising antibody therapy for various kinds of cancer. In general, T-BsAbs have dual-binding specificity to a tumor-associated antigen and a CD3 subunit forming a… read more here.
Keywords: antitumor immunity; cell bispecific; bispecific antibodies; cell ... See more keywords